Tango Therapeutics, Inc. (TNGX) Revenue History
Annual and quarterly revenue from 2019 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
TNGX Revenue Growth
Revenue Breakdown (FY 2025)
TNGX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
TNGX Revenue Analysis (2019–2025)
As of May 8, 2026, Tango Therapeutics, Inc. (TNGX) generated trailing twelve-month (TTM) revenue of $62.4 million, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q4 2025) recorded $0 in revenue, down 100.0% sequentially.
Looking at the longer-term picture, TNGX's 5-year compound annual growth rate (CAGR) stands at +52.1%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $62.4 million in 2025, representing a new all-time high.
Revenue diversification analysis shows TNGX's business is primarily driven by Collaboration Revenue (100%). With over half of revenue concentrated in Collaboration Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including KYMR (-12.6% YoY), and AUPH (+20.4% YoY), TNGX has underperformed the peer group in terms of revenue growth. Compare TNGX vs KYMR →
TNGX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| TNGXCurrent | $62M | -100.0% | +52.1% | -178.4% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 AUPH | $283M | +20.4% | +41.4% | 37.1% |
TNGX Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $62.4M | +48.3% | $60.1M | 96.3% | $-111,289,000 | -178.4% |
| 2024 | $42.1M | +15.2% | $42.1M | 100.0% | $-145,595,000 | -346.1% |
| 2023 | $36.5M | +46.9% | $36.5M | 100.0% | $-114,173,000 | -312.6% |
| 2022 | $24.9M | -32.9% | $24.9M | 100.0% | $-111,071,000 | -446.8% |
| 2021 | $37.0M | +383.8% | $37.0M | 100.0% | $-58,190,000 | -157.1% |
| 2020 | $7.7M | -68.9% | $6.0M | 78.8% | $-52,200,000 | -681.8% |
| 2019 | $24.6M | - | $-7,625,000 | -30.9% | $-15,162,000 | -61.5% |
See TNGX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TNGX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TNGX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTNGX — Frequently Asked Questions
Quick answers to the most common questions about buying TNGX stock.
Is TNGX's revenue growth accelerating or slowing?
TNGX revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of +52.1%. TTM revenue fell to $62M. This reverses the prior growth trend.
What is TNGX's long-term revenue growth rate?
Tango Therapeutics, Inc.'s 5-year revenue CAGR of +52.1% reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is TNGX's revenue distributed by segment?
TNGX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2025 are available for download. Segment mix reveals concentration and diversification trends.